Author Correction: Multiple sclerosis.
Where this comes from
- Record sourced from PubMed, PMID 30467372.
- Also identified by DOI 10.1038/s41572-018-0050-3.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the originally published version of this article, in Table 4, Ocrelizumab was incorrectly referred to as an anti-CD25 antibody. This has been corrected in the HTML and PDF versions of the article to an anti-CD20 antibody.